Litong Yao

703 total citations
32 papers, 462 citations indexed

About

Litong Yao is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Litong Yao has authored 32 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Cancer Research, 11 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Litong Yao's work include Breast Cancer Treatment Studies (7 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Litong Yao is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Litong Yao collaborates with scholars based in China, Australia and United States. Litong Yao's co-authors include Mengshen Wang, Haoran Dong, Mozhi Wang, Xiangyu Sun, Xinyan Li, Tie Sun, Jingyi Guo, Xueting Yu, Yingying Xu and Yingying Xu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Oncogene.

In The Last Decade

Litong Yao

27 papers receiving 460 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Litong Yao China 11 262 199 113 60 51 32 462
Feng Dong China 10 281 1.1× 204 1.0× 39 0.3× 118 2.0× 29 0.6× 18 439
Huo Wu China 12 233 0.9× 89 0.4× 82 0.7× 22 0.4× 15 0.3× 16 439
Tyler M. Hudish United States 8 155 0.6× 83 0.4× 79 0.7× 53 0.9× 29 0.6× 8 343
Jianchao Wang China 13 203 0.8× 136 0.7× 70 0.6× 15 0.3× 42 0.8× 34 381
Qiang Sun China 15 319 1.2× 238 1.2× 239 2.1× 74 1.2× 30 0.6× 41 663
Bo Zeng China 12 149 0.6× 65 0.3× 107 0.9× 113 1.9× 35 0.7× 32 440
Mónica Higuera Spain 12 286 1.1× 84 0.4× 39 0.3× 42 0.7× 77 1.5× 21 558

Countries citing papers authored by Litong Yao

Since Specialization
Citations

This map shows the geographic impact of Litong Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Litong Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Litong Yao more than expected).

Fields of papers citing papers by Litong Yao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Litong Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Litong Yao. The network helps show where Litong Yao may publish in the future.

Co-authorship network of co-authors of Litong Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Litong Yao. A scholar is included among the top collaborators of Litong Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Litong Yao. Litong Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sun, Tie, Mozhi Wang, Litong Yao, et al.. (2025). Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis. BMC Cancer. 25(1). 115–115. 3 indexed citations
3.
Zhang, Qiang, Yumeng Li, Hengjun Zhang, et al.. (2025). Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial. Signal Transduction and Targeted Therapy. 10(1). 169–169. 3 indexed citations
4.
Dong, Haoran, et al.. (2024). ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis. Cancer Biology and Medicine. 21(7). 1–30. 7 indexed citations
5.
6.
Zhang, Yingfan, Chenxin Wang, Meng Li, et al.. (2024). Zinc finger protein 593 promotes breast cancer development by ensuring DNA damage repair and cell-cycle progression. iScience. 27(12). 111513–111513. 1 indexed citations
7.
Yao, Litong, et al.. (2024). Phase separation in DNA damage response: New insights into cancer development and therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1879(6). 189206–189206. 6 indexed citations
8.
9.
10.
Yao, Litong, Yuwei Li, Siyuan Li, et al.. (2023). ARHGAP39 is a prognostic biomarker involved in immune infiltration in breast cancer. BMC Cancer. 23(1). 440–440. 4 indexed citations
11.
Sun, Xiangyu, Qiang Zhang, Mozhi Wang, et al.. (2023). Acyl-CoA thioesterase 7 is oncogenic in breast cancer by promoting oxidative phosphorylation via PGC1α. Genes & Diseases. 11(5). 101149–101149.
12.
Jiao, Jinghua, Honghua Yu, Litong Yao, et al.. (2021). Recent Insights into the Role of Gut Microbiota in Diabetic Retinopathy. Journal of Inflammation Research. Volume 14. 6929–6938. 23 indexed citations
13.
Yao, Litong, Xinyu Wang, Yifan Zhong, et al.. (2021). The Triglyceride–Glucose Index is Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes: A Hospital-Based, Nested, Case–Control Study. Diabetes Metabolic Syndrome and Obesity. Volume 14. 1547–1555. 27 indexed citations
14.
Yao, Litong, Mozhi Wang, Mengshen Wang, et al.. (2021). The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study. Cancer Biology and Medicine. 19(5). 755–767. 6 indexed citations
15.
Yao, Litong, Shuang Li, Mengshen Wang, et al.. (2021). An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector Machine. Frontiers in Oncology. 11. 651809–651809. 4 indexed citations
16.
Li, Xinyan, Litong Yao, Mozhi Wang, et al.. (2020). Updated Bayesian Network Meta-Analysis of Adjuvant Targeted Treatment Regimens for Early Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer. Journal of Breast Cancer. 23(4). 410–410. 1 indexed citations
17.
Yao, Litong, Yifan Zhong, Yan Wang, et al.. (2020). <p>Serum CA125 Level Is Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes</p>. Diabetes Metabolic Syndrome and Obesity. Volume 13. 1803–1812. 4 indexed citations
18.
Sun, Xiangyu, Mozhi Wang, Mengshen Wang, et al.. (2020). Metabolic Reprogramming in Triple-Negative Breast Cancer. Frontiers in Oncology. 10. 428–428. 156 indexed citations
19.
Sun, Xiangyu, Mozhi Wang, Mengshen Wang, et al.. (2020). Role of Proton-Coupled Monocarboxylate Transporters in Cancer: From Metabolic Crosstalk to Therapeutic Potential. Frontiers in Cell and Developmental Biology. 8. 651–651. 53 indexed citations
20.
Yao, Litong, Yifan Zhong, Jingyang Wu, et al.. (2019). <p>Multivariable Logistic Regression And Back Propagation Artificial Neural Network To Predict Diabetic Retinopathy</p>. Diabetes Metabolic Syndrome and Obesity. Volume 12. 1943–1951. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Feng Dong Breakdown of academic impact, for papers by Huo Wu Breakdown of academic impact, for papers by Tyler M. Hudish Breakdown of academic impact, for papers by Jianchao Wang Breakdown of academic impact, for papers by Qiang Sun Breakdown of academic impact, for papers by Bo Zeng Breakdown of academic impact, for papers by Mónica Higuera
Rankless by CCL
2026